ANDS Anadys Pharma announces issuance of U.S. patent covering setrobuvir (ANA598) (1.20 -0.04)
Co announced issuance of the U.S. patent covering setrobuvir (ANA598), the Company's Direct-Acting Antiviral (DAA) in Phase IIb development for chronic hepatitis C virus infection (HCV). U.S. Patent No. 7,939,524, granted to Anadys by the United States Patent and Trademark Office, recognizes the Company's intellectual property rights to the composition of matter and methods of use for setrobuvir (ANA598) and related compounds.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.